Canna~Fangled Abstracts A phase 1/2, open-label assessment of the safety, tolerability, and efficacy of transdermal cannabidiol (ZYN002) for the treatment of pediatric fragile X syndrome. J Neurodev Disord. 2019 Aug 2;11(1):16. doi: 10.1186/s11689-019-9277-x. Heussler H1,2, Cohen J3, Silove N4, Tich…Freedom WaresAugust 2, 2019
